A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Folic acid (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 17 Apr 2023 Status changed from recruiting to completed.
- 25 Sep 2013 Planned End Date changed from 1 Aug 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
- 31 May 2013 A total of 26 out of the planned accrual of 100 patients have been enrolled as reported in an ASCO 2013 abstract.